


Understanding treatment preferences of patients with atypical hemolytic uremic syndrome (aHUS)



Ravulizumab

Eculizumab

Quantitative survey

● Treatment preference

● Patient- and caregiver-reported impact on quality of life



Adult patients with aHUS (n = 50)



Caregivers of pediatric patients with aHUS (n = 16)




Adult patients with aHUS

94%



Preference for ravulizumab over eculizumab

100%



Caregivers of pediatric patients with aHUS

Main reasons for preference



Benefit to quality of life




Ability to go to work/school



Frequency of infusions




Reasons



Infusion duration



Ability to travel/go on vacation



Ability to control aHUS

Adult patients and caregivers of pediatric patients show an overall preference for ravulizumab